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626 The Journal of Thoracic and Cardbjective: Oxygen-derived free radicals are responsible in part for reperfusion
njury in globally ischemic myocardium. In this study, the efficacy for resuscitation
f nonbeating donor hearts of MCI-186, a free-radical scavenger and antioxidant,
as investigated in a pig transplantation model.
ethods: Cardiac arrest was induced by asphyxiation. After 30 minutes of global
schemia, the hearts were excised and immediately reperfused from the aortic root
ith normoxemic blood cardioplegia (PO2 100 mm Hg) for 20 minutes, followed by
erfusion with hyperoxemic blood (PO2 300 mm Hg). MCI-186 (3 mg/kg) was
dministered into the aortic root for the first 30 minutes of reperfusion in the treated
roup (n  6), and untreated hearts were used as a control group (n  6).
ransplantation was performed with the heart beating.
esults: Posttransplantation recovery of cardiac output, end-systolic pressure–volume
atio, and first derivative of pressure of the left ventricle in the treated group were
ignificantly better than those in the control group. The coronary sinus–aortic root
ifference in malondialdehyde levels remained low throughout reperfusion in the
reated group but abruptly increased after initiation of oxygenated blood perfusion
n the control group. The MCI-186–treated hearts showed low degree of edema and
ell-preserved ultrastructure with normal-appearing organelles, whereas the un-
reated hearts had marked swelling of mitochondria and scant glycogen granules.
onclusion: MCI-186 exerts a cardioprotective action at least partly by inhibition of
ipid peroxidation. Antioxidant therapy at the initial reperfusion is essential to
uccessful resuscitation of nonbeating hearts by continuous myocardial perfusion.
n increasing lack of brain-dead donors and a growing number of patients in
need of cardiac transplantation has prompted clinicians to reevaluate the
potential use of cardiac allograft from non–heart beating donors (NHBDs).
his treatment strategy has not yet been used beyond the laboratory, however,
ecause profound myocardial damage developing during an indeterminate period of
arm ischemia is unavoidable. Recent studies in animal models have shown that
reservation of NHBD cardiac graft with simple cardioplegic flush and hypothermic
torage allows functional recovery only when multiple cardioprotective pretreat-
ents are used.1,2 Because any treatment before death in anticipation of pos
onation is ethically unacceptable, establishment of legally defensible techniques
or resuscitation of cadaver hearts and of specific measures for myocardial protec-
ion after death is critical to ensure the feasibility of using such donor hearts for
uman transplantation.
Investigators in 1960s attempted to restore canine and human cadaver hearts by
esumption of coronary perfusion with normothermic oxygenated blood3,4 but
ithout consideration of reperfusion injury. When cardiomyocytes are reoxygenatedfter a prolonged period of ischemia, cytosolic calcium overload and reactivation of
iovascular Surgery ● June 2007
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TXnergy production cause deleterious hypercontracture5
hus the initial reperfusion should maintain cardiac arrest,
llowing a brief interval where ionic balance can recover
ore normally during reoxygenation. To reduce myocardial
schemia before transplantation, we have attempted to re-
uscitate nonbeating hearts with a continuous myocardial
erfusion technique, but without the use of any cardiopro-
ective pretreatments. Recent work from our laboratory
emonstrated the importance of the duration of the initial
ontrolled reperfusion with leukocyte-depleted lukewarm
lood cardioplegic solution.6
There is a wealth of evidence that oxygen free radicals
lay major roles in ischemia–reperfusion injury.7 On reper-
usion, molecular oxygen undergoes sequential reduction to
orm reactive species of oxygen, including superoxide anion
nd hydroxyl radical. The interaction of oxygen-derived
ree radicals with lipids and essential proteins in the cell
embrane contributes to myocardial damage.8 MCI-186
3-methyl-1-phenyl-2-pyrazolin-5-one) is an interesting
ompound with unique pharmacologic actions; it can act as
 hydroxyl radical scavenger9 and has antioxidant effects o
oth hydroxyl radical–dependent and iron-dependent lipid
eroxidation.10,11 In Japan, this agent has been used c-
ally to treat patients with cerebral infarction,12 and its
europrotective effects are indisputable. In this study we
nvestigated the cardioprotective effects of MCI-186 on
earts obtained from asphyxiated NHBDs in a pig trans-
lantation model by administration of this agent during the
nitial reperfusion.
aterials and Methods
nimal Preparation
ll experimental animals were cared for in accordance with insti-
utional guidelines and the “Guide for the Care and Use of Labo-
atory Animals” (http://www.nap.edu/catalog/5140.html). The e
erimental protocol was approved by the Okayama University
chool of Medicine experimental animals committee. Twelve
eight-matched pairs of Yorkshire pigs (male or female, mean
eight 20  3 kg) were used. Another pig was used for blood
onation at each experiment. After premedication with intramus-
ular injection of 10-mg/kg ketamine hydrochloride, an ear vein
as cannulated, and anesthesia was induced with 50 mg thiamylal
odium and 0.5 mg atropine sulfate and maintained with isoflurane
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
LV  left ventricle
MDA malondialdehyde
MDA  difference in MDA level between the
coronary sinus and the aortic root
NHBD non–heart beating donornhalation (0.5%–2.0%) and 0.2-mg/kg pancuronium. An endotra- s
The Journal of Thoracicheal tube was inserted through a tracheostomy, and mechanical
entilation was begun with a tidal volume of 10 mL/kg.
After a median sternotomy, heparin (500 U/kg) was given
ntravenously. Catheters were inserted into the carotid artery, the
nternal jugular vein, and the left atrium for pressure monitoring. A
F thermodilution catheter was inserted into the pulmonary artery
runk for measurement of cardiac output. A 3F pressure-tip cath-
ter (Millar Instruments, Inc, Houston, Tex) and a conductance
atheter (2S-RH6DA-116; Alpha Medical Instruments, Mission
iejo, Calif) were inserted from the apex into the left ventricle
LV). A 3F catheter was placed in the coronary sinus to obtain
lood samples.
xperimental Protocol
sphyxiation was induced by turning the ventilator off. After
ardiac arrest was achieved with standstill or ventricular fibrilla-
ion, the animals were left for 30 minutes at room temperature. The
eart, including both atria, ventricles, and the aortic arch, was
xcised and weighed. After insertion of a perfusion cannula into
he aortic root, the ascending aorta was clamped, and then isolated
ontinuous myocardial perfusion was performed by cardiopulmo-
ary bypass (CPB) with blood cardioplegic solution at 20°C with
 perfusion pressure of 40 mm Hg for 20 minutes (Figure 1
igure 1. Isolated myocardial perfusion. Blood cardioplegia and
lood were infused into coronary arteries through aortic root
annula. MCI-186 was directly infused into coronary artery by
solated myocardial perfusion.olution was composed of leukocyte-depleted normoxemic (PO2
and Cardiovascular Surgery ● Volume 133, Number 6 1627
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TXbout 100 mm Hg) oxygenated blood mixed with a modified St
homas’ Hospital solution (20% D-mannitol 100 mL, sodium
icarbonate 19 mEq, potassium chloride 18.5 mEq, magnesium
ulfate 37 mEq, in 1 L 5% glucose) in a 4:1 ratio. Myocardial
erfusion was then switched with leukocyte-depleted hyperoxemic
xygenated blood (PO2 about 300 mm Hg) at 20°C with a perfu-
ion pressure of 40 mm Hg. After 20 minutes, the perfusion
ressure was elevated to 60 mm Hg, and the temperature was
ncreased stepwise to 37°C during a period of 30 minutes.
In the treated group (n  6), administration of MCI-186 (3
g/kg) was begun at the time of reperfusion and continued for 30
inutes (until 10 minutes after the initiation of blood reperfusion).
he coronary effluent was discarded to keep MCI-186 concentra-
ion at a constant level in the circuit. We selected the most
ffective doses and infusion period of MCI-186 on the basis of
ell-established dose-response studies of this agent in reperfusion
njury.13,14 The remaining 6 pigs did not receive MCI-186 at
ime during the experiment and served as a control group.
Another CPB circuit incorporating a pediatric oxygenator
D902 Lilliput 2; Dideco SpA, Mirandola, Italy), filled with 500 mL
onated blood, 10,000 units heparin, and 500 mg methylprednisolone,
as established by bicaval and aortic cannulation in a recipient animal
nd was maintained with a flow rate of 75 mL/(kg · min). At this
tage, orthotopic heart transplantation was performed with the
onor heartbeat being maintained by continuous myocardial per-
usion. Two hours after aortic unclamping, animals were weaned
rom CPB with an infusion of 0.1 g/(kg · min) epinephrine. At
he end of each experiment, the animals were killed by intravenous
njection of potassium chloride.
ardiac Function
ardiac function was assessed before asphyxiation for baseline
alues. Because respiratory function after transplantation deterio-
ated with time as result of LV dysfunction, measurements were
epeated 1 hour after weaning from CPB. Cardiac output was
easured by the thermodilution method. LV end-systolic pressure–
olume ratio was calculated from pressure–volume relation curves
uring transit volume unloading induced by the occlusion of both
enae cavae. Maximum and minimum of first derivative of LV
ressure were obtained from a pressure curve acquired with a
igh-fidelity micromanometer catheter. Calibration for blood con-
uctivity was performed just before each measurement.
etermination of Malondialdehyde and Myocardial
raction of Creatine Kinase
lood samples were collected from the aorta and the coronary
ffluent before anoxia (baseline value), at 5 minutes and 10 min-
tes during the controlled initial reperfusion with blood cardiople-
ic solution, and subsequently at 5, 10, 20, 30, 60, 120, and 180
inutes during the perfusion with oxygenated blood. The plasma
oncentration of malondialdehyde (MDA) was determined with a
ommercially available colorimetric assay kit (MDA-586 assay
it; OXIS International Inc, Foster City, Calif). The difference in
DA level between the coronary sinus and the aortic root
MDA) was calculated. The myocardial fraction of creatine ki-
ase was determined by a chemiluminescence immunoassay and
xpressed as a percentage of total creatine kinase. w
628 The Journal of Thoracic and Cardiovascular Surgery ● Junyocardial Edema
he wet weight of the heart including the aortic arch was measured
t the time of excision of the donor heart and at the end of the
xperiment. The posterior wall thickness of the LV was measured
y surface echocardiography with short-axis imaging at the level
f papillary muscles before asphyxiation and after transplantation.
istopathologic Examination
iopsy specimens were taken from the LV anterior wall of the
eating heart after assessment of posttransplantation cardiac func-
ion. For light microscopic examination, the specimens were fixed
n 10% buffered formaldehyde, embedded in paraffin, cut into
-m thick sections, and stained with hematoxylin and eosin. For
ransmission electron microscopic study, specimens were fixed in
hosphate-buffered (pH 7.4) glutaraldehyde (1%) and paraformal-
ehyde (2%), postfixed in osmium tetroxide (2%), and embedded
n epoxy. Ultrathin sections were stained with uranyl acetate and
ead citrate. A Hitachi H7100 electron microscope (Hitachi, Ltd,
okyo, Japan) was used to study the sections. Morphologic eval-
ation was performed by a blinded observer (C.Y.).
tatistical Analysis
he Wilcoxon signed rank test was used for comparison between
aseline and posttransplantation values. Statistical significance of
ny difference between the groups was determined with the Mann–
hitney test. Analysis of variance was used to compare MDA.
esults are given as mean  SD unless otherwise indicated.
esults
here were no significant differences between the groups in
he agonal period (time from the initiation of asphyxiation
o cardiac arrest), warm ischemic time, implantation time,
nd CPB time (Table 1). Baseline values of each variab
ardiac function measured before asphyxiation did not dif-
er between the groups. Flow rate during the initial 20-
inute reperfusion with blood cardioplegia increased from
0 mL/min to 65 mL/min, indicating reduction in coronary
esistance. All hearts started beating slowly approximately 5
inutes after blood reperfusion, spontaneously recovered
egular rhythm, and were successfully weaned from CPB.
eart rate, mean pulmonary arterial pressure, left atrial
ressure, and central venous pressure after transplantation
ABLE 1. Procedure variables
Control group Treated group
gonal period (min) 9 1 9  1
arm ischemic time (min) 36 1 37 1
mplantation time (min) 72 7 73 5
ardiopulmonary bypass time (min) 218 6 217  7
ll values expressed as mean SD. No differences between groups were
ignificant. The agonal period was the time from initiation of asphyxiation
o cardiac arrest; the warm ischemic time was the time from cardiac arrest
o the beginning of initial controlled reperfusion; the implantation time was
he time taken for anastomoses.ere significantly higher than baseline values but did not
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TXhange until 1 hour after CPB (Table 2). The posttrans
ation recovery rates of cardiac output, LV end-systolic
ressure-volume ratio, and maximum and minimum of first
erivative of LV pressure in the treated group remained at
pproximately 80% of baseline values but were all signifi-
antly better than those in the control group (Table 3
The changes in MDA during reperfusion are shown in
igure 2. MDA in the treated group remained low through-
ut the reperfusion. On the other hand, MDA in the control
roup abruptly increased after initiation of oxygenated
lood perfusion, although values were low during the initial
eperfusion with blood cardioplegia. Release of the myo-
ardial fraction of creatine kinase, an index of myocyte
njury, increased after transplantation in both groups, but the
ean enzyme level in the treated group was significantly
ower than that in the control group (323  56 IU/L vs
41  161 IU/L, P  .05).
Although heart weight increased after transplantation in
oth groups, weight gain in the treated group was signifi-
antly less than in the control group (6%  2% vs 11% 
%, P  .05). LV posterior wall thickness increased after
ransplantation in all hearts, but the mean thickening of the
reated hearts was significantly smaller than that of the
ntreated hearts (11%  3% vs 20%  4%, P  .05).
Hematoxylin–eosin staining demonstrated smaller eosin-
philic myocardial changes, less edema, and less vacuolar
egeneration in the treated group than in the control group,
lthough fundamental myocardial structures were preserved
n both groups (Figure 3). Transmission electron mi
raphs demonstrated that the myocardium of the untreated
ABLE 2. Hemodynamic variables
Con
BT PT after
eart rate (beats/min) 92 11 123
ean arterial pressure (mm Hg) 60 7 47 
ean pulmonary arterial pressure (mm Hg) 12 2 25 
eft atrial pressure (mm Hg) 3 2 6 
entral venous pressure (mm Hg) 1 1 5 
T, Before transplantation; PT, posttransplantation; CPB, cardiopulmonar
ransplantation.
ABLE 3. Recovery rate of cardiac function
BT
ardiac output (L/min) 1.9 0.3
V end-systolic pressure–volume ratio (mm Hg/mL) 4.8 0.3
aximum LV developed pressure (mm Hg/s) 1180 280
inimum LV developed pressure (mm Hg/s) 829 204T, Before transplantation; PT, posttransplantation; LV, left ventricular. All valu
The Journal of Thoracic-earts had marked swelling of mitochondria, with disrup-
ion of the cristae, dilated endoplasmic reticulum, and scant
lycogen granules. In contrast, the treated hearts showed
ell-preserved ultrastructure, including mitochondria with
egular cristae. Other organelles, such as endoplasmic retic-
lum, Golgi apparatus, T-tubules, and so on were of normal
ppearance (Figure 4). These findings indicated that th
as no irreversible ischemic change in the treated hearts.
iscussion
lthough a number of approaches to procurement of ca-
aver hearts have been studied in the laboratory, understand-
ng of the outcomes is confounded by several experimental
actors. Martin and colleagues15 showed well-preserved myo-
ardial viability 24 hours after transplantation from exsangui-
ated NHBDs by refined preservation techniques but with-
ut pretreatment. There is some evidence, however, that
eath from asphyxiation in a possible cardiac allograft
HBD causes more severe myocardial damage than does
eath from exsanguination.16 Regarding postmortem isch-
mic time, a Pittsburgh group17 reported that in the patien
ndergoing liver and kidney transplantation from NHBDs
hose families had requested that life support be withdrawn
category 3, The Maastricht International Workshop18), the
ean interval between cardiac arrest and thoracic aorta
rossclamping was 24 minutes. We used pigs in this study
ecause of similarities of the myocardium and the coronary
natomy to those of human beings. To mimic the category
NHBD situation, we used the asphyxiation model and set
he duration of postmortem ischemia at 30 minutes.
roup Treated group
PT 1 h after CPB BT PT after CPB PT 1 h after CPB
128  14* 91 10 120 13* 125 8*
50  10* 59  12 48 3* 53 5*
26  7* 13  3 22  5* 23 5*
6  2* 2  2 6  2* 6 2*
7  3* 1  1 5  2* 6 2*
ass. All values expressed as mean  SD. *P  .05 versus value before
trol group Treated group
PT
Recovery rate
(%) BT PT
Recovery rate
(%)
 0.1 60 10 2.0  0.2 1.6  0.1 81 5*
 0.3 62 7 4.8  0.5 4.0  0.3 82 4*
 105 63 8 1219  249 1024  101 86 10*
 116 64 8 824  115 726  62 89 8*trol g
CPB
10*
5*
3*
2*
2*
y bypCon
1.2
3.0
723
524es expressed as mean  SD. *P  .05 versus control group.
and Cardiovascular Surgery ● Volume 133, Number 6 1629
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1
TXResuscitation of nonbeating hearts by early resumption
f myocardial perfusion is beneficial in reducing ischemia.
eleterious events initiated by reperfusion, however, such
s myocardial hypercontracture, cytotoxic reactive oxygen
pecies, complement activation, and neutrophil adhesion,
an result in irreversible tissue injury. We recently reported
hat controlled initial reperfusion with leukocyte-depleted
ukewarm blood cardioplegia at 40 mm Hg for 20 minutes
rovided better posttransplantation graft function than if the
nitial reperfusion lasted for 5 or 60 minutes, although the
ecovery rate was at best 60%.6 Results of this study dem-
nstrate that supplementation of the reperfusate with MCI-
86 reduced leakage of the myocardial fraction of creatine
inase, prevented myocardial edema, preserved better myo-
ardial structure, and enhanced functional recovery, indicat-
ng that antioxidant therapy at the initiation of reperfusion is
ssential to successful resuscitation of nonbeating hearts.
The main sources of free-radical production in myocar-
ial tissue in ischemia-reperfusion are thought to involve
he xanthine oxidase–hypoxanthine system, the electron
ransmission system in mitochondria, and the arachidonic
ascade and the reduced nicotinamide adenosine diphos-
hate oxidase system in polymorphonuclear white blood
ells. Although superoxide generated as the initial radical
hrough these systems is less toxic, the most potent oxidizer,
he hydroxyl radical, can be formed from superoxide by an
ron-catalyzed Haber–Weiss reaction.7 Hydroxyl radical ac-
elerates lipid peroxidation of cell membranes, which
auses increased permeability of membrane structures of all
he main organelles to calcium ion, resulting in hypercon-
racture of myofibrils.8 In addition, the metabolites of a-
hidonic acid, which are produced through the lipoxygenase
athways, exert deleterious cardiovascular effects. Leuko-
Figure 2. Changes in coronary difference in levels o
Values are mean  SD.rienes, hydroxyeicosatraenoic acids, and hydroxyeicosatet- t
630 The Journal of Thoracic and Cardiovascular Surgery ● Junaenoic acids induce vasoconstriction, particularly constric-
ion of the coronary vascular beds. Japanese investigators
ave reported that MCI-186 scavenges hydroxyl radica9
nhibits the lipoxygenase pathway in the arachidonic acid cas-
ade,19,20 and prevents both hydroxyl radical– dependent 
ron-dependent lipid peroxidation of the cell membrane.10,11
MDA originates from an oxygen free radical–mediated
reakdown of peroxidized phospholipids.21 In this study
nhancement of posttransplantation functional recovery in
CI-186–treated hearts was associated with marked sup-
ression of MDA production, suggesting that this com-
ound exerts its cardioprotective property through inhibi-
ion of detrimental lipid peroxidation. Although MDA
uring the controlled initial reperfusion with normoxemic
lood cardioplegia remained at negligible levels in both
roups, values in the untreated group increased after con-
ersion of the perfusion solution to hyperoxemic blood.
hnken and associates22 found in their hypoxemic pigl
odels that acute reoxygenation (400 mm Hg) by CPB
educed the antioxidant reserve capacity and that normox-
mic blood cardioplegia further suppressed lipid peroxida-
ion and better preserved cardiac contractility than did hy-
eroxemic blood cardioplegia. Taking these findings with
ur results, we suspect that normoxemic blood cardioplegia
tself may have antioxidant effects and that acute reoxygen-
tion, which can lead to a burst of free-radical generation,
hould be avoided during continuous myocardial perfusion
n nonbeating hearts.
To determine the optimal timing and duration of admin-
stration of antioxidant agents, it is important to identify the
xact time window during which free radical–mediated
yocardial damage occurs. Previous studies demonstrated
hat free-radical scavengers exert cardioprotective proper-
ondialdehyde (MDA) between sinus and aortic root.f malies when they are administered just before or at the time
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TXf reperfusion after total or regional global ischemi23
hereas no such effect manifests when they are given 1
inute after initiation of reperfusion. Although we admin-
stered MCI-186 during the first 30 minutes of reperfusion,
rom beginning of the controlled initial reperfusion with
ormoxemic blood cardioplegia until 10 minutes after hy-
eroxemic blood perfusion, the antioxidant effect of MCI-
86 assessed by MDA production was noticed immediately
fter conversion of perfusion solution to hyperoxem
lood. Because free-radical generation and subsequent tis-
ue injury are proportionate to PaO2,24,25 gradual reoxygen-
tion during reperfusion could avoid a burst of free radicals
n globally ischemic hearts.
Myocardial edema is associated with cardiac dysfunc-
ion; as edema accumulates within the interstitial spaces,
nterstitial pressure rises, thus increasing the stiffness and
ecreasing the compliance of both ventricles.26,27 Blood
ardioplegia itself causes edema through the combination of
ncreased myocardial fluid filtration and decreased cardiac
ymph drainage.28 The hearts in both groups increased
all thickness and weight and showed significant edema
fter transplantation, but the MCI-treated hearts had less
dema than did the untreated hearts. Our results indicate that
CI-186 exerts its cardioprotective effects at least in part
y preventing myocardial edema.
For the last three decades, effects of global ischemia on
he myocardium have been extensively investigated in ex-
erimental animal models, but conclusions with regard toThe Journal of Thoraciche degree of myocardial injury and its reversibility have
een controversial. Schaper and coworkers29 studied the
ffects of various durations of global ischemia and reperfu-
ion in the myocardium of isolated dog hearts and showed
hat although functional, biochemical, and ultrastructural
hanges tended to recover during the reperfusion phase,
ven in severely injured hearts except “stone heart,” the
econstitution of the myocardial ultrastructure occurred at a
aster rate than did recovery of other parameters. Subcellu-
ar structural integrity thus may be a prerequisite for revers-
ble ischemic injury. Because the MCI-treated hearts had
ell-preserved ultrastructure, further improvement of car-
iac function can be expected by longer support with con-
inuous myocardial perfusion before transplantation.
In conclusion, without the use of any cardioprotective
retreatment, resuscitation of nonbeating pig hearts ob-
ained after 30 minutes of global ischemia is feasible by
eans of continuous myocardial perfusion, initially with
eukocyte-depleted lukewarm-blood cardioplegia for 20
inutes and then with oxygenated blood. A free-radical
cavenger, MCI-186, when administered for the first 30
inutes of reperfusion provides better preservation of myo-
ardial structure and enhanced recovery of cardiac function
fter transplantation, at least in part by inhibition of lipid
eroxidation. Before NHBDs are used in human heart trans-
lantation, modalities to determine transplantability must be
stablished. At this time, electron microscopy of small
issue samples obtained during resuscitation appears to be
Figure 3. Light micrographs of un-
treated myocardium (A) and MCI-186–
treated myocardium (B) after trans-
plantation (hematoxylin–eosin, 40).
Figure 4. Transmission electron micro-
graphs of untreated myocytes (A) and
MCI-186–treated myocytes (B) after
transplantation (hematoxylin–eosin,
10000).and Cardiovascular Surgery ● Volume 133, Number 6 1631
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TXhe only clinically applicable method to estimate the revers-
bility of the ischemic state of the heart. 29
We thank Ms. Masumi Furutani (Central Research Laboratory,
kayama University Graduate School of Medicine and Dentistry),
kiko Itagaki, and Saori Tsukuda for technical assistance.
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